Canadian Cancer Society Report: Nearly 1 in 2 Canadians Expected to Be Diagnosed With Cancer in Their Lifetime

Nearly 1 in 2 Canadians is expected to be diagnosed with cancer in their lifetime, according to a new report—Canadian Cancer Statistics 2017—released by the Canadian Cancer Society (CCS) in partnership with the Public Health Agency of Canada and Statistics Canada. For males, the lifetime risk is 49%, and for females, it is 45%. This puts an enormous burden on individuals, the health-care system, and services and research supported by cancer charities. CCS is calling on the public to invest in cancer research and prevention efforts to reduce the impact of cancer on Canadians.

“This sobering statistic highlights the fact that cancer is a disease that will touch almost all of us in some way,” said Leah Smith, PhD, MSc, CCS epidemiologist and one of the report’s authors. “Almost half of us will be diagnosed with at least one form of cancer at some point during our lifetime. In addition, 1 in 4 Canadians will die of cancer. That might be your spouse, your parent, your child, or you. The good news is we can do something about it. About half of all cancers can be prevented, and research continues to improve the outlook for people with cancer.”

Reasons for Rising Rates

CCS emphasizes that the rise in cancer cases is primarily being driven by an aging and growing population. According to the report, an estimated 206,200 Canadians will be diagnosed with cancer this year, and almost 90% of these cases will be among Canadians 50 years of age and older. As more people live into old age, the number of cancer cases will continue to rise.

Progress and Challenges

Great progress has been made in the fight against cancer, but there is much more work to be done. Because of investments in cancer control including prevention, early detection, and treatment, the overall cancer survival rate has increased from about 25% in the 1940s to 60% today. Some cancers, like thyroid and testicular malignancies, have a 5-year net survival of over 90%.

For other cancers, such as pancreatic cancer, there is an urgent need for more research investment. Pancreatic cancer has the lowest survival rate of all the major cancers, at only 8%. Very little progress has been made against this disease, especially compared to other major cancers. As a result, it is expected to soon be the third leading cause of cancer death in Canada.

Taking Action

“This report underscores how important it is to focus on healthy behaviors and healthy public policies to reduce the number of people hearing the words ‘you have cancer’ each year,” said Dr. Smith. “Actions like quitting smoking, eating well, being physically active, and practicing sun safety, along with appropriate cancer screening tests, can go a long way toward reducing your risk of getting cancer.”

Research is also a critical piece of the puzzle. Investments in cancer research will lead to better prevention, enhanced screening, earlier diagnosis, more targeted and effective treatments, improved quality of life and, ultimately, fewer cancer cases and deaths.

CCS invested $40 million in cancer research in 2016, and the Government of Canada invests in cancer control in many ways, including funding the Canadian Partnership Against Cancer and the Canadian Institutes of Health Research.

“Every single Canadian is affected by cancer in some way, and we need to ensure we support patients and families with better research, education, treatment, and support,” said the Honourable Jane Philpott, Minister of Health. “We are committed to working with our partners, including the Canadian Cancer Society, to continue to help people with cancer to live longer and have a better quality of life.”

“Thanks in part to our donors, CCS is able to invest in the most promising research in Canada,” said Dr. Smith. “But the reality is last year, 60% of high-priority research projects went unfunded because of the money we had available. Imagine the impact we could have if we were able to fund 100%.”

The content in this post has not been reviewed by the American Society of Clinical Oncology, Inc. (ASCO®) and does not necessarily reflect the ideas and opinions of ASCO®.




By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.